We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simple One-Hour Saliva Test Detects Common Cancers

By LabMedica International staff writers
Posted on 09 Mar 2026

Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. More...

Researchers are exploring simpler approaches that could enable rapid screening using readily collected samples, such as saliva. Scientists have developed a new saliva-based test that detects a protein biomarker associated with several cancer types within approximately one hour.

Researchers at Queensland University of Technology (QUT; Brisbane, Australi) have developed a portable diagnostic method to detect the protein biomarker S100P, which has been linked to oral, colon, pancreatic, prostate, and several other cancers. The test uses a paper-based sensor coated with gold and silver nanoparticles. These particles enable a detection technique known as surface-enhanced Raman spectroscopy (SERS), which identifies molecules based on how they scatter laser light.

The researchers created a paper sensor that selectively captures the S100P biomarker from saliva samples. To prepare the sensor, antibodies were chemically attached to the nanoparticle-coated paper using a light-driven synthesis process with deep ultraviolet LEDs. Once the biomarker binds to the sensor, the system records the Raman spectrum of the sample, allowing detection of S100P without requiring complex laboratory processing. The team also developed a target-specific paper extraction chip that isolates the biomarker before analysis, improving detection accuracy. The resulting method, published in Talanta, provides a rapid and low-cost way to detect S100P using a saliva sample.

Because the test uses saliva rather than blood or tissue biopsies, it may offer a noninvasive screening approach that could potentially be used in point-of-care settings. The paper-based sensor also reduces manufacturing costs and avoids complex chemical processes typically used in biomarker detection. Researchers suggest that the technology could help identify cancers or precancerous changes earlier, allowing doctors to intervene sooner. Further studies will be required to validate the method before it can be implemented in clinical screening programs.

“This method could shorten diagnosis time to minutes instead of hours or days and uses low-cost and portable materials,” said Associate Professor Emad Kiriakous, PhD.

Related Links:
Queensland University of Technology


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.